基于Web of Science的非酒精性脂肪肝病治疗研究可视化分析

朱宝强; 张明名; 杨诗语; 胡佳强; 李文渊; 龙恩武

doi:10.6039/j.issn.1001-0408.2023.18.13

您当前的位置：

首页 >

文章列表页 >

基于Web of Science的非酒精性脂肪肝病治疗研究可视化分析

药物与临床 | 更新时间：2023-09-22

- 基于Web of Science的非酒精性脂肪肝病治疗研究可视化分析
- Visual analysis of the treatment of non-alcoholic fatty liver disease based on Web of Science
- 中国药房 2023年34卷第18期页码：2243-2249
- 作者机构：
  
  1.西南医科大学药学院，四川泸州　646000
  2.四川省医学科学院·四川省人民医院/电子科技大学附属医院药学部，成都　610072
  3.电子科技大学医学院，成都　610054
- 作者简介：
  
  药师，硕士研究生。研究方向：临床药学。E-mail：zbq160911@163.com
  主任药师，硕士生导师，博士。研究方向：临床药学。E-mail：dragon984169@126.com
- 基金信息：
  
  中国研究型医院学会药物评价专委会《临床重点药品的使用监测和评价研究专项课题》(Y2022FH-YWPJ01-201);个体化药物治疗四川省重点实验室开放和自拟课题(2021YB06)
- DOI：10.6039/j.issn.1001-0408.2023.18.13
  中图分类号： R975
- 纸质出版日期：2023-09-30，
  
  收稿日期：2023-05-04，
  
  修回日期：2023-08-28，
扫描看全文
朱宝强,张明名,杨诗语等.基于Web of Science的非酒精性脂肪肝病治疗研究可视化分析 ^Δ[J].中国药房,2023,34(18):2243-2249.

ZHU Baoqiang,ZHANG Mingming,YANG Shiyu,et al.Visual analysis of the treatment of non-alcoholic fatty liver disease based on Web of Science[J].ZHONGGUO YAOFANG,2023,34(18):2243-2249.
朱宝强,张明名,杨诗语等.基于Web of Science的非酒精性脂肪肝病治疗研究可视化分析 ^Δ[J].中国药房,2023,34(18):2243-2249. DOI： 10.6039/j.issn.1001-0408.2023.18.13.

ZHU Baoqiang,ZHANG Mingming,YANG Shiyu,et al.Visual analysis of the treatment of non-alcoholic fatty liver disease based on Web of Science[J].ZHONGGUO YAOFANG,2023,34(18):2243-2249. DOI： 10.6039/j.issn.1001-0408.2023.18.13.

摘要

目的

分析非酒精性脂肪肝病（NAFLD）治疗研究现状、热点及发展趋势，为后续研究提供参考。

方法

检索Web of Science数据库，收集建库起至2022年12月31日治疗NAFLD的相关文献，利用CiteSpace 6.1.R6构建可视化图谱，对作者、国家及机构进行合作网络分析，同时进行关键词共现、聚类和突现分析，分析其研究现状和热点。

结果

共纳入文献3 882篇，发文量呈逐年增长的趋势。发文量排名前3位的国家为中国、美国和日本。发文量最多的作者是美国的Sanyal（37篇），发文量最多的机构是加州大学圣地亚哥分校（75篇）。国外联系紧密的研究团队以大型随机对照试验（RCT）为主，对包括药物、生活方式等多种干预措施治疗NAFLD的有效性和安全性进行了评估；而国内研究以有效药用成分治疗NAFLD的基础研究为主，且以中医药为特色，相关的高质量大型RCT较少。关键词分析结果显示，各国研究以调控肝脏氧化应激和炎症、改善全身糖脂代谢平衡为主，除降糖药物外，作用于多种综合调控体内代谢稳态靶点的药物进入临床试验阶段，具有巨大的治疗潜力。

结论

NAFLD治疗研究热度持续增长，并以调控全身代谢稳态靶点和相关药物为研究导向。作为研究主力，我国应加强与国际的交流，把握基础研究的趋势，重视临床研究的开展，不断挖掘传统中药的治疗潜力。

Abstract

OBJECTIVE

To analyze the current status， hotspots and development trends of research on the treatment of non-alcoholic fatty liver disease （NAFLD）， providing reference for subsequent research.

METHODS

Searching the Web of Science database， the literature related to the treatment of NAFLD from the establishment of the database to December 31， 2022 were collected. CiteSpace 6.1.R6 was used to construct a visual atlas， perform collaborative network analysis on authors， countries and institutions， and conduct keyword co-occurrence， clustering and emergence analysis to explore its research status and hotspots.

RESULTS

A total of 3 882 articles were included， and the number of publications had been increasing year by year. The top three countries in terms of publication volume were China， the United States， and Japan. The author with the highest volume of publications was Sanyal from the United States （37 articles）， while the institution with the highest volume of publications was the University of California， San Diego （75 articles）. A closely connected research team abroad mainly conducted large-scale randomized controlled trials （RCT） to evaluate the effectiveness and safety of various interventions， including medication and lifestyle， in treating NAFLD. However， domestic researches mainly focused on basic researches about the treatment of NAFLD with effective medicinal ingredients， and were characterized by traditional Chinese medicine. There were relatively few high-quality large-scale RCT studies related to it. Keyword analysis showed that researches in various countries mainly focused on regulating liver oxidative stress and inflammation， improving the overall balance of glucose and lipid metabolism. Except for hypoglycemic drugs， drugs that act on various comprehensive metabolic homeostasis targets in the body had entered clinical research， and had enormous therapeutic potential.

CONCLUSIONS

The research on NAFLD treatment continues to grow in popularity and tends to research targets and drugs for regulating systemic metabolic homeostasis. As the main force of research， China should strengthen communication with the international community， grasp the trends and directions of basic research， attach importance to clinical research， and continuously tap the therapeutic potential of traditional Chinese medicine.

关键词

非酒精性脂肪肝病治疗CiteSpaceWeb of Science可视化分析

Keywords

therapyCiteSpaceWeb of Sciencevisual analysis

references

周宗涛，邓利明，胡丽君，等. 非酒精性脂肪肝药物治疗靶点及药物研究进展[J]. 中国新药杂志，2020，29（12）：1363-1374.

ESLAM M，NEWSOME P N，SARIN S K，et al. A new definition for metabolic dysfunction-associated fatty liver disease：an international expert consensus statement[J]. J Hepatol，2020，73（1）：202-209.

ZHOU Y F，HU Z Z，YUAN H，et al. CiteSpace-based visual analysis of hypothermia studies in surgical patients[J]. Nurs Open，2023，10（9）：6228-6236.

LINDOR K D，KOWDLEY K V，HEATHCOTE E J，et al. Ursodeoxycholic acid for treatment of nonalcoholic stea-tohepatitis：results of a randomized trial[J]. Hepatology，2004，39（3）：770-778.

CALDWELL S H，PATRIE J T，BRUNT E M，et al. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis[J]. Hepatology，2007，46（4）：1101-1107.

NOBILI V，MANCO M，DEVITO R，et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease：a randomized，controlled trial[J]. Hepatology，2008，48（1）：119-128.

GAWRIEH S，NOUREDDIN M，LOO N，et al. Saroglitazar，a PPAR-α/γ agonist，for treatment of NAFLD：a randomized controlled double-blind phase 2 trial[J]. Hepato-logy，2021，74（4）：1809-1824.

YOUNOSSI Z M，STEPANOVA M，NADER F，et al. Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis：regenerate 18-month interim analysis[J]. Clin Gastroenterol Hepatol，2022，20（9）：2050-2058.e12.

YUE S R，TAN Y Y，ZHANG L，et al. Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic stea-tohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway[J]. Front Endocrinol，2022，13：885039.

DAI L，XU J J，LIU B C，et al. Lingguizhugan decoction，a Chinese herbal formula，improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease：a translational approach[J]. Front Med，2022，16（5）：745-759.

CUSI K，ISAACS S，BARB D，et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings：co-sponsored by the American Association for the Study of Liver Diseases（AASLD）[J]. Endocr Pract，2022，28（5）：528-562.

徐万鹏，梁英琴，韦秀桂，等. 老鼠簕生物碱A对大鼠非酒精性脂肪肝的改善作用及其机制研究[J]. 中国药房，2020，31（16）：1955-1960.

CAO C J，SHI M X，WANG X R，et al. Effects of probiotics on non-alcoholic fatty liver disease：a review of human clinical trials[J]. Front Nutr，2023，10：1155306.

ZHANG C S，TENG Y L，LI F Q，et al. Nanoparticle-mediated RNA therapy attenuates nonalcoholic steatohepatitis and related fibrosis by targeting activated hepatic stellate cells[J]. ACS Nano，2023，17（15）：14852-14870.

段蓉，李正翔. 国内外药物警戒研究现状与热点的文献计量学分析[J]. 中国药房，2022，33（1）：116-122.

BANDYOPADHYAY S，SAMAJDAR S S，DAS S. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis：a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol，2023，47（7）：102174.

GOYAL N P，MENCIN A，NEWTON K P，et al. An open label，randomized，multicenter study of elafibranor in children with nonalcoholic steatohepatitis[J]. J Pediatr Gastroenterol Nutr，2023，77（2）：160-165.

FRANCQUE S M，BEDOSSA P，RATZIU V，et al. A randomized，controlled trial of the pan-PPAR agonist lanifibranor in NASH[J]. N Engl J Med，2021，385（17）：1547-1558.

NAKAJIMA A，EGUCHI Y，YONEDA M，et al. Randomised clinical trial：pemafibrate，a novel selective peroxisome proliferator-activated receptor α modulator（SPPARMα），versus placebo in patients with no-nalcoholic fatty liver disease[J]. Aliment Pharmacol Ther，2021，54（10）：1263-1277.

YOUNOSSI Z M，RATZIU V，LOOMBA R，et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis：interim analysis from a multicentre，randomised，placebo-controlled phase 3 trial[J]. Lancet，2019，394（10215）：2184-2196.

PATEL K，HARRISON S A，ELKHASHAB M，et al. Cilofexor，a nonsteroidal FXR agonist，in patients with noncirrhotic NASH：a phase 2 randomized controlled trial[J]. Hepatology，2020，72（1）：58-71.

RATZIU V，RINELLA M E，NEUSCHWANDER-TETRI B A，et al. EDP-305 in patients with NASH：a phase Ⅱ double-blind placebo-controlled dose-ranging study[J]. J Hepatol，2022，76（3）：506-517.

李政，陈莲如，刘玉霞. 非酒精性脂肪肝病药物研究进展[J]. 聊城大学学报（自然科学版），2023，36（2）：68-78.

NEWSOME P N，BUCHHOLTZ K，CUSI K，et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med，2021，384（12）：1113-1124.

ARMSTRONG M J，GAUNT P，AITHAL G P，et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis（LEAN）：a multicentre，double-blind，randomised，placebo-controlled phase 2 study[J]. Lancet，2016，387（10019）：679-690.

HARTMAN M L，SANYAL A J，LOOMBA R，et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes[J]. Diabetes Care，2020，43（6）：1352-1355.

RIZZO M，COLLETTI A，PENSON P E，et al. Nutraceutical approaches to non-alcoholic fatty liver disease（NAFLD）：a position paper from the International Lipid Expert Panel（ILEP）[J]. Pharmacol Res，2023，189：106679.

SANYAL A，CHARLES E D，NEUSCHWANDER-TETRI B A，et al. Pegbelfermin（BMS-986036），a PEGylated fibroblast growth factor 21 analogue，in patients with non-alcoholic steatohepatitis：a randomised，double-blind，placebo-controlled，phase 2a trial[J]. Lancet，2019，392（10165）：2705-2717.

LI L M，SONG Y，SHI Y Q，et al. Thyroid hormone receptor-β agonists in NAFLD therapy：possibilities and challenges[J]. J Clin Endocrinol Metab，2023，108（7）：1602-1613.

RATZIU V，SANYAL A，HARRISON S A，et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis：final analysis of the phase 2b centaur study[J]. Hepatology，2020，72（3）：892-905.

XIE W T，SU F G，WANG G Z，et al. Glucose-lowering effect of berberine on type 2 diabetes：a systematic review and meta-analysis[J]. Front Pharmacol，2022，13：1015045.

JIANG J J，ZHANG G F，ZHENG J Y，et al. Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity[J]. Front Pharmacol，2022，13：876550.

阮小风，张建军，杜鹏，等. 基于CiteSpace软件的非酒精性脂肪性肝病治疗的可视化分析[J]. 华南国防医学杂志，2019，33（12）：815-822.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于CiteSpace可视化分析复发高级别胶质瘤的治疗研究现状

2013－2023年中医药治疗溃疡性结肠炎的文献计量学分析

人工智能应用于医院药学服务领域的文献计量学分析

酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析

我国中成药临床综合评价研究热点与趋势分析